GSK cheers investors with asthma drug sales, big dividend

LONDON — Drugmaker GlaxoSmithKline saw it shares rise Wednesday after it said it was sticking to a generous dividend and that its blockbuster asthma medicine, Advair, was weathering competition from generic versions.

Shares rose almost 4 percent after the company said sales increased about 1 percent in the fourth quarter from a year earlier to 7.6 billion pounds. The company also cheered investors by keeping the dividend unchanged at 80 pence a share.

The company nonetheless posted a fourth-quarter loss of 546 million pounds ($758 million) from a profit of 257 million pounds a year earlier. The company said the impact of U.S. tax changes reduced earnings by 1.63 billion pounds.

CEO Emma Walmsley said that improving the pharmaceuticals business remains GSK's "main priority," and that it was strengthening two current therapy areas, respiratory and HIV, and two potential areas, oncology and immuno-inflammation.

The company is bracing, meanwhile, for competition in the coming year in the respiratory and HIV businesses. The company says it can see a potential for a generic version of its blockbuster asthma drug, Advair.

Like many pharma companies, GSK is trying to continue to deliver growth as older treatments lose patent protection and new generic products eat away at profit margins.

But Nicholas Hyett, an equity analyst at Hargreaves Lansdown, said GSK has benefited from the fact that the company's rivals have so far struggled to get a generic version of Advair past U.S. regulators.

"GSK is seeing sales of its respiratory blockbuster hold up better than expected. However, the looming increase in competition remains a ticking time bomb under the group," he said. "Advair accounts for 10 percent of group sales — if a generic makes it to market early next year, it will blow a hole in the GSK income statement."

You may also interested in

Tesla's Autopilot system under scrutiny in fatal...

Sep 15, 2016

Tesla faces new scrutiny in China about its vehicle Autopilot system after state television...

Winds may finally clear 'scary' pollution from...

Dec 21, 2016

The dense smog that has smothered much of China for five days may soon clear, giving relief to...

Argentine soccer star Carlos Tevez signs $40M...

Dec 29, 2016

Argentine striker Carlos Tevez has signed to play for Shanghai Shenhua, becoming the latest in a...

China pledges further cuts in excess steel, coal...

Jan 10, 2017

China's top economic planner has pledged to continue cutting steel and coal production, which have...

Chinese factory makes giant inflatable...

Jan 13, 2017

A Chinese factory has been doing a brisk business selling giant inflatable roosters, some as tall...

People also read these

China's electric vehicle industry shaken by...

Sep 13, 2016

China's electric vehicle industry, a flagship for Beijing's technology ambitions, has been rocked...

Tesla's Autopilot system under scrutiny in fatal...

Sep 15, 2016

Tesla faces new scrutiny in China about its vehicle Autopilot system after state television...

Asian stocks markets retreat after Wall Street...

Dec 23, 2016

Most Asian stock markets have declined in thin trading ahead of the Christmas holiday after Wall...

McDonald's sells China business in deal worth up...

Jan 9, 2017

Fast-food giant McDonald's is selling a controlling stake in its China business to a group of...

China aircraft carrier capabilities tested on...

Jan 14, 2017

China's sole aircraft carrier has returned home following a three-week cruise during which its...

About Us

Frontal Report is an emerging leader in all forms of media. We aim to be the leading news brand for readers around the world.

Contact us: sales@frontalreport.com

Subscribe Now!